{"id":4434,"date":"2020-08-26T09:20:23","date_gmt":"2020-08-26T09:20:23","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/proadm-proven-to-be-the-best-risk-predictor\/"},"modified":"2021-01-08T11:29:23","modified_gmt":"2021-01-08T11:29:23","slug":"proadm-proven-to-be-the-best-risk-predictor","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/proadm-proven-to-be-the-best-risk-predictor\/","title":{"rendered":"ProADM proven to be the best risk predictor"},"content":{"rendered":"

The new biomarker ProADM significantly improves risk assessment of patients suffering from lower respiratory tract infection (LRTI)<\/strong><\/p>\n

An early risk assessment of LRTI patients is essential for optimizing treatment and rational resource allocation. Adrenomedullin (ADM) has a significant presence in the course of LRTI and is strongly associated with a patient\u2019s risk of mortality and severe complications. ADM reflects a patient\u2019s risk profile while its elevation is independent of the LRTI etiology.
\nA robust method to assess ADM levels is the measurement of a stable surrogate marker, the mid-regional fragment of ProAdrenomedullin (MR-proADM). The only available automated immunoassay is from Thermo Fisher Scientific. <\/p>\n

Features of ProADM (MR-proADM) measurement<\/strong>
\n\u2022 Directly reflective of ADM production in a 1:1 ratio
\n\u2022 Increased stability relative to ADM
\n\u2022 Reliably measurable with the automated Thermo Scientific B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S MR-proADM KRYPTOR immunoassay
\n\u2022 Well documented for clinical use
\n\u2022 Rapidly available to aid timely clinical decision-making (assay incubation time 29 minutes)
\n\u2022 Small sample volume (26\u00b5L)
\n\u2022 Measurement in EDTA plasma  <\/p>\n

>> read more on www.thermoscientific.com\/ProAdrenomedullin<\/link><\/strong>
\n
\nSupplier:<\/strong> Thermo Fisher Scientific
\nWebsite:<\/strong> <\/a><\/p>\n

Mail the supplier<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

The new biomarker ProADM significantly improves risk assessment of patients suffering from lower respiratory tract infection (LRTI) An early risk assessment of LRTI patients is essential for optimizing treatment and rational resource allocation. Adrenomedullin (ADM) has a significant presence in the course of LRTI and is strongly associated with a patient\u2019s risk of mortality and […]<\/p>\n","protected":false},"author":2,"featured_media":11174,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[39],"tags":[],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/4434"}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=4434"}],"version-history":[{"count":0,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/4434\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media\/11174"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=4434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=4434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=4434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}